Investigating the therapeutic effect of tetrabenazine in psychiatric patients with drug complications

Investigating the effect of tetrabenazine in the treatment of tardive dyskinesia in psychiatric patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240308061212N1

Enrollment

Registered

2024-05-03

Start date

2024-04-08

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tardive Dyskinesia. Drug induced dystonia

Interventions

Intervention 1: Intervention group: The treatment plan is to start tetrabenazine with a dose of 12.5 mg per day for the case group and increase the dose to 25 mg in the second week and then increase t

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having a diagnosis of tardive dyskinesia disorder Having at least one diagnosis of mood or psychotic disorders Having the ability to give informed consent Having a minimum age of 18 years and a maximum age of 65 years

Exclusion criteria

Exclusion criteria: History of neurological diseases such as epilepsy, Parkinson's, stroke and ischemic cardiac problems History of tetrabenazine allergy

Design outcomes

Primary

Measure	Time frame
AIMS test scores. Timepoint: The AIMS test will be conducted at the beginning and the 8th week of the study. Method of measurement: AIMS Movement Disorders Test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnaz Moghaddampour

Zanjan University of Medical Sciences

gmoghaddampour@gmail.com+98 24 3354 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026